Page 234 - 2021_06-Haematologica-web

Letters to the Editor
Table 1. Baseline characteristics of patients with large-cell lymphoma based on CRM1 protein expression on primary tumor cells.
Variable
Sex, n, (%) Female Male
Diagnosis Age
Median, years, (range) Subtype, n, (%)
DLBCL
Mediastinal large B-cell
Initial Treatment, n, (%)
MR-CHOP Other IC R-CHOP R-EPOCH R-HYPERCVAD R2-CHOP RAD-RCHOP RCHOP/Zevalin
Stage Group n, (%) I-II
III-IV
LDH Group n, (%)
Missing/unknown ≤ Normal n, (%) > Normal n, (%)
ECOG PS Group <2
CRM1-low (N=100)
42 (42.0) 58 (58.0)
59.0 (20.0 - 84.0)
98 (98.0) 2 (2.0)
6 (6.0)
4 (4.0) 66 (66.0) 16 (16.0) 1 (1.0) 6 (6.0) 1 (1.0) 0 (0.0)
42 (42.0) 58 (58.0)
15
47 (55.3) 38 (44.7)
81 (81.0) 19 (19.0)
85 (85.0)
15 (15.0)
17 (17.0) 29 (29.0) 26 (26.0) 19 (19.0) 9 (9.0)
0 (0.0)
28
40 (55.6) 32 (44.4)
52
16 (33.3) 32 (66.7)
8 (8.0) 89 (89.0) 3 (3.0)
CRM1-high (N=182)
74 (40.7) 108 (59.3)
61.5 (18.0 - 93.0)
177 (97.3) 5 (2.7)
16 (8.8) 3 (1.6) 122 (67.0) 23 (12.6) 3 (1.6) 12 (6.6) 2 (1.1) 1 (0.5)
80 (44.0) 102 (56.0)
17
83 (50.3) 82 (49.7)
144 (79.1) 38 (20.9)
151 (83.0)
31 (17.0)
27 (14.8) 43 (23.6) 51 (28.0) 41 (22.5) 17 (9.3) 3 (1.6)
38
92 (63.9) 52 (36.1)
84
32 (32.7) 66 (67.3)
10 (5.5) 164 (90.1) 8 (4.4)
P
0.827
0.239
0.7
0.845
0.751
0.454
0.707
0.658
0.692
0.236
0.934
0.617
≥2 Num. ≤1 >1
Extranodal Group n, (%)
(%)
IPI 0 1 2 3 4 5
n,
Cell of origin per Hans criteria
Missing/unknown GCB n, (%) non-GCB n, (%)
Cell of origin per Nanostring Missing/unknown
ABC n, (%)
GCB n, (%)
MYC Double Hit (FISH) n, (%)
Missing/unknown Negative
Positive
2262
ABC: activated B-cell; CRM1: chromosome region maintenance protein1; DLBLC: diffuse large B-cell lymphoma; IPI: international prognostic index; GCB: germinal center B- cell; FISH: fluorescent in-situ hybridization; LDH: lactate dehydrogenase; MR-CHOP: methotrexate, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; RCHOP: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R-EPOCH: rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin; R-HYPERCVAD: rituximab, cyclophosphamide, vincristine, doxorubicin and dexamethasone; R2-CHOP: revlimid, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; RAD-RCHOP: radiation with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
haematologica | 2021; 106(8)